ReviewFrontiers in cellular and infection microbiology2021
Protein Kinases: Potential Drug Targets Against
Review in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Antimicrobial Resistance and the Blood-Brain Barrier: Complex Interactions and Implications for Neurological Health.Molecular neurobiology · 2025Review
- In silico design of a multi-epitope pan vaccine targeting Schistosoma species.Genomics & informatics · 2025Article
- Protein phosphorylation networks in Baylisascaris procyonis revealed by phosphoproteomic analysis.Parasites & vectors · 2025Article
- Hepatocyte nuclear factor 4 located in different developmental stages of Schistosoma japonicum and involved in important metabolic pathways.Biomedical journal · 2025Article
- Schistosomiasis Chemotherapy, Chemoprevention, and Vaccines: History, Progress, and Priorities.Immunity, inflammation and disease · 2024Review
- Receptor Tyrosine Kinase Signaling InvolvesTropical medicine and infectious disease · 2024Review
- Advances in the study of the interaction between schistosome infections and the host's intestinal microorganisms.Parasites & vectors · 2024Review
- Targeting SmCB1: Perspectives and Insights to Design Antischistosomal Drugs.Current medicinal chemistry · 2024Review
- Identification of potent schistosomicidal compounds predicted as type II-kinase inhibitors againstFrontiers in parasitology · 2024Article
- Will AMPK be a potential therapeutic target for hepatocellular carcinoma?American journal of cancer research · 2024Review
- Article
- Chemical modulation ofWellcome open research · 2023Article
- Hidden in plain sight: How helminths manage to thrive in host blood.Frontiers in parasitology · 2023Review
- Toward novel treatment against filariasis: Insight into genome-wide co-evolutionary analysis of filarial nematodes andFrontiers in microbiology · 2023Article
- A global phosphoproteomics analysis of adult Fasciola gigantica by LC-MS/MS.Parasitology research · 2022Article
- Discovery of Schistosoma mekongi circulating proteins and antigens in infected mouse sera.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.